PET/CT Imaging of NSCLC with a α v β 6 Integrin-Targeting Peptide

Purpose Targeted therapies are regarded as promising approaches to increase 5-year survival rate of non-small cell lung cancer (NSCLC) patients. Here, we investigated the clinical value of the αvβ6 integrin-specific peptide SFITGv6 as a diagnostic reagent targeting NSCLC.